Figure 2

Effect of Ribavirin on cytokine levels. (a) Heatmap of median fold change of soluble marker levels in plasma compared to healthy donors for all measured cytokines in CHC patients who received a DAA regimen with (+RBV) or without (−RBV) Ribavirin. (b) Evolution of markers concentration (median ± IQR) in CHC patients over the course of treatment. Dotted lines and shaded area represent the median and 95% confidence interval of the median for healthy donors. (c) Comparison between healthy donors (HD) and CHC patients who received a DAA regimen with (+RBV) or without (−RBV) Ribavirin. BL: baseline; W4: week 4; EOT: end of treatment; FU: follow-up.